Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 8/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13804412 | 0.88 | PTK2 (0.36) | PIN1PTK2KMT2A | |
| SCHEMBL12749380 | 0.88 | PTK2 (0.37) | PIN1PTK2KMT2A | |
| SCHEMBL12749188 | 0.87 | PTK2 (0.36) | PIN1PTK2KMT2A | |
| SCHEMBL12749384 | 0.86 | KMT2A (0.37) | PIN1PTK2IGF1RGSK3BMEN1 | |
| SCHEMBL12749379 | 0.85 | PTK2 (0.38) | PTK2 | |
| SCHEMBL1612184 | 0.84 | PTK2 (0.44) | PTK2 | |
| SCHEMBL12749386 | 0.84 | PTK2 (0.35) | PIN1PTK2KMT2A | |
| SCHEMBL12749347 | 0.84 | PTK2 (0.41) | PIN1PTK2KMT2A | |
| SCHEMBL12749387 | 0.74 | SYK (0.33) | PTK2 | |
| SCHEMBL12717452 | 0.73 | PTK2 (0.44) | PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | PIN1 2268/4885PTK2 833/4885IGF1R 493/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | PIN1 2268/4885PTK2 833/4885IGF1R 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.